Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of LY-M003 injection in adults with Wilson disease
CTR20262097Phase 2Active
- Sponsor
- Lingyi Biotechnology
- Start
- May 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LY-M003 in Wilson disease (WD), sponsored by Lingyi Biotechnology. Started May 2026; status: active.
02
Drugs
LY-M003
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on CTR20262097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262097.